Table 4.
Intratumor heterogeneity of KRAS oncogene point mutations in codon 12 in the group of 31 NSCLC patients harboring this mutation in at least 2 of 5 separate cancer tissue samples obtained after complete tumor resection
| Number of patients | Fraction of KRAS mutation positive cancer tissue samples | Histological diagnosis SCC/ADC/LCNEC |
Number of identified KRAS point mutations in KRAS mutation positive cancer tissue samples | ||||
|---|---|---|---|---|---|---|---|
| G12D | G12V | G12C | G12A | G12S | |||
| Patients presenting with intratumor heterogeneity of KRAS oncogene point mutations (n = 14) | |||||||
| 5 | 5/5 | 2/3/0 | 2 | 3 | 0 | 0 | 0 |
| 3 | 5/5 | 3/0/0 | 3 | 2 | 0 | 0 | 0 |
| 2 | 5/5 | 2/0/0 | 0 | 3 | 2 | 0 | 0 |
| 2 | 5/5 | 2/0/0 | 2 | 0 | 3 | 0 | 0 |
| 1 | 5/5 | 1/0/0 | 2 | 0 | 0 | 0 | 3 |
| 1 | 5/5 | 0/1/0 | 1 | 0 | 4 | 0 | 0 |
| Patients not presenting with intratumor heterogeneity of KRAS oncogene point mutations (n = 17) | |||||||
| 10 | 5/5 | 4/5/1 | 5 | 0 | 0 | 0 | 0 |
| 2 | 5/5 | 1/1/0 | 0 | 0 | 0 | 5 | 0 |
| 1 | 5/5 | 1/0/0 | 0 | 5 | 0 | 0 | 0 |
| 2 | 4/5 | 0/2/0 | 4 | 0 | 0 | 0 | 0 |
| 1 | 3/5 | 0/0/1 | 3 | 0 | 0 | 0 | 0 |
| 1 | 2/5 | 0/1/0 | 2 | 0 | 0 | 0 | 0 |
Intratumor heterogeneity of mutated sequence was noted when at least two different mutated sequences were detected in analyzed samples of cancer tissue. One patient with adenosquamous cell carcinoma who had KRAS point mutation G12D in one of five cancer tissue samples is not shown in the table
NSCLC non-small cell lung cancer, SCC squamous cell carcinoma, ADC adenocarcinoma, LCNEC large cell neuroendocrine carcinoma